Logo image of TENX

TENAX THERAPEUTICS INC (TENX) Stock Fundamental Analysis

NASDAQ:TENX - Nasdaq - US88032L6056 - Common Stock - Currency: USD

5.46  +0.36 (+7.06%)

After market: 5.5 +0.04 (+0.73%)

Fundamental Rating

3

Overall TENX gets a fundamental rating of 3 out of 10. We evaluated TENX against 568 industry peers in the Biotechnology industry. While TENX has a great health rating, there are worries on its profitability. TENX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TENX had negative earnings in the past year.
TENX had a negative operating cash flow in the past year.
TENX had negative earnings in each of the past 5 years.
TENX had a negative operating cash flow in each of the past 5 years.
TENX Yearly Net Income VS EBIT VS OCF VS FCFTENX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

TENX has a Return On Assets of -18.21%. This is in the better half of the industry: TENX outperforms 79.93% of its industry peers.
The Return On Equity of TENX (-19.13%) is better than 86.97% of its industry peers.
Industry RankSector Rank
ROA -18.21%
ROE -19.13%
ROIC N/A
ROA(3y)-136.22%
ROA(5y)-220.51%
ROE(3y)-284.78%
ROE(5y)-368.86%
ROIC(3y)N/A
ROIC(5y)N/A
TENX Yearly ROA, ROE, ROICTENX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TENX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TENX Yearly Profit, Operating, Gross MarginsTENX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

TENX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TENX has more shares outstanding
TENX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TENX Yearly Shares OutstandingTENX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
TENX Yearly Total Debt VS Total AssetsTENX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -1.49, we must say that TENX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TENX (-1.49) is comparable to the rest of the industry.
TENX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.49
ROIC/WACCN/A
WACCN/A
TENX Yearly LT Debt VS Equity VS FCFTENX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

TENX has a Current Ratio of 20.60. This indicates that TENX is financially healthy and has no problem in meeting its short term obligations.
TENX's Current ratio of 20.60 is amongst the best of the industry. TENX outperforms 94.89% of its industry peers.
A Quick Ratio of 20.60 indicates that TENX has no problem at all paying its short term obligations.
The Quick ratio of TENX (20.60) is better than 94.89% of its industry peers.
Industry RankSector Rank
Current Ratio 20.6
Quick Ratio 20.6
TENX Yearly Current Assets VS Current LiabilitesTENX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

TENX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.96%, which is quite impressive.
EPS 1Y (TTM)84.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TENX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.87% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y83.51%
EPS Next 2Y34.71%
EPS Next 3Y22.69%
EPS Next 5Y16.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TENX Yearly Revenue VS EstimatesTENX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2027 2028 2029 2030 2031 2032 200M 400M 600M
TENX Yearly EPS VS EstimatesTENX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5K -10K -15K -20K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TENX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TENX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TENX Price Earnings VS Forward Price EarningsTENX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TENX Per share dataTENX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

TENX's earnings are expected to grow with 22.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.71%
EPS Next 3Y22.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TENX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TENAX THERAPEUTICS INC

NASDAQ:TENX (4/23/2025, 5:20:00 PM)

After market: 5.5 +0.04 (+0.73%)

5.46

+0.36 (+7.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25 2025-03-25/amc
Earnings (Next)05-12 2025-05-12
Inst Owners61.26%
Inst Owner Change0%
Ins Owners0.28%
Ins Owner Change0%
Market Cap21.68M
Analysts88
Price Target22.44 (310.99%)
Short Float %11.23%
Short Ratio8.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)72.42%
Min EPS beat(2)58.23%
Max EPS beat(2)86.6%
EPS beat(4)3
Avg EPS beat(4)31.75%
Min EPS beat(4)-27.45%
Max EPS beat(4)86.6%
EPS beat(8)6
Avg EPS beat(8)24.36%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)37.5%
PT rev (3m)27.54%
EPS NQ rev (1m)60.54%
EPS NQ rev (3m)71.43%
EPS NY rev (1m)68.18%
EPS NY rev (3m)70.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB 0.24
EV/EBITDA N/A
EPS(TTM)-5.32
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-3.73
FCFYN/A
OCF(TTM)-3.73
OCFYN/A
SpS0
BVpS23.17
TBVpS23.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.21%
ROE -19.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-136.22%
ROA(5y)-220.51%
ROE(3y)-284.78%
ROE(5y)-368.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.6
Quick Ratio 20.6
Altman-Z -1.49
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.61%
EPS Next Y83.51%
EPS Next 2Y34.71%
EPS Next 3Y22.69%
EPS Next 5Y16.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-136.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-150.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-150.88%
OCF growth 3YN/A
OCF growth 5YN/A